sixty rabbits with liver vx2 tumors were assigned into five groups of 12 rabbits each, which received 4 mg of doxorubicin via intravenous injection (iv group), hepatic arterial infusion (ia group), conventional tace (ctace group), csm-tace (csm low-dose group), and 8 mg of doxorubicin via csm-tace (csm high-dose group), respectively. doxorubicin concentrations in plasma, tumor, and adjacent hepatic parenchyma were measured at various timepoints after treatment, and tumor necrosis percentage and liver enzymes were also assessed.
将60只vx2肝肿瘤家兔分为5组，每组12只，分别通过静脉注射(iv组)、肝动脉灌注(ia组)、常规tace (ctace组)、csm-tace (csm低剂量组)接受4 mg多柔比星，csm-tace注射8 mg多柔比星(csm高剂量组)。在治疗后的不同时间点测定血浆、肿瘤和邻近肝实质中多柔比星的浓度，并评估肿瘤坏死率和肝酶。
the peak plasma concentration of doxorubicin was significantly lower in the three tace groups compared to iv and ia group (p<0.05), while doxorubicin concentrations in tumor and adjacent hepatic parenchyma were higher in the two csm groups compared with iv, ia, and ctace groups at 3 days and 7 days after treatment (p<0.05). the percentages of tumor necrosis at 3 and 7 days after treatment were significantly higher in three tace groups (all higher than 50%) compared with iv group and ia group (both lower than 25%) (p<0.05), and the highest tumor necrosis percentage was achieved in csm high-dose group. the three tace groups showed transient increases in transaminases levels after treatment, in which the peak transaminases levels were significantly lower in the two csm groups than those in ctace group (p<0.05).
与iv组和ia组相比，ctace组、csm低剂量组和csm高剂量组多柔比星的血浆浓度峰值显著降低(p < 0.05)，在治疗后3天和7天，csm低剂量组和csm高剂量组肿瘤和邻近的肝实质多柔比星的浓度较iv组和ia组更高(p < 0.05)。治疗后3天和7天，ctace组、csm低剂量组和csm高剂量组肿瘤坏死率(均高于50%)均显著高于iv组和ia组(均低于25%) (p < 0.05)，其中csm高剂量组肿瘤坏死率最高。三个tace组治疗后转氨酶水平均有短暂升高，其中csm低剂量组和csm高剂量组转氨酶峰值水平显著低于ctace组(p < 0.05)。
csm achieves an effective delivery of doxorubicin into liver cancer. high-dose doxorubicin improves tumoricidal capacity while not impairing the safety of the doxorubicin-loaded csm.